Obstetrics & Gynaecology
Polycystic Ovary Syndrome (GTG 33)
Polycystic Ovary Syndrome (GTG 33) clinical pathway.
Source: RCOG; ESHRE; NICE — RCOG GTG 33 (2014), NICE CKS PCOS
Step 1 of ~4
info
Diagnosis (Rotterdam Criteria)
Diagnostic criteria:
• Oligo/anovulation
• Clinical or biochemical hyperandrogenism
• Polycystic ovaries on ultrasound (≥12 follicles or volume ≥10ml)
Requirement: 2 of 3 criteria + exclusion of other causes
Exclusions:
• Congenital adrenal hyperplasia
• Androgen-secreting tumours
• Cushing's syndrome
• Thyroid dysfunction
• Hyperprolactinaemia
Adolescents: Do not diagnose <2 years post-menarche; need both hyperandrogenism + irregular cycles
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Methylene Blue · Guanylate Cyclase / Nitric Oxide Pathway Inhibitor
- Aciclovir 800mg Tablets (Ramsay Hunt Syndrome / Herpes Zoster Oticus) · Antiviral — nucleoside analogue (herpes zoster treatment)
- Sodium phenylbutyrate · Ammonia scavenger (alternative pathway)
- Pramipexole (Restless Legs Syndrome — Elderly) · Dopamine Agonist (D2/D3 Receptor)
- Marstacimab · Anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody
- Prednisolone (Paediatric) · Corticosteroid — Asthma Exacerbation / Croup / Nephrotic Syndrome / IBD
Decision support only. Always apply local guidelines and clinical judgement.